SI1567529T1 - Psevdopolimorfne oblike zaviralca HIV proteaze - Google Patents

Psevdopolimorfne oblike zaviralca HIV proteaze

Info

Publication number
SI1567529T1
SI1567529T1 SI200332389T SI200332389T SI1567529T1 SI 1567529 T1 SI1567529 T1 SI 1567529T1 SI 200332389 T SI200332389 T SI 200332389T SI 200332389 T SI200332389 T SI 200332389T SI 1567529 T1 SI1567529 T1 SI 1567529T1
Authority
SI
Slovenia
Prior art keywords
protease inhibitor
hiv protease
pseudopolymorphic forms
pseudopolymorphic
forms
Prior art date
Application number
SI200332389T
Other languages
English (en)
Other versions
SI1567529T2 (sl
Inventor
Hans Wim Pieter Vermeersch
Daniel Joseph Christiaan Thone
Luc Donne Marie-Louise Janssens
Piet Bert Paul Wigerinck
Original Assignee
Janssen R&D Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29724454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1567529(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen R&D Ireland filed Critical Janssen R&D Ireland
Publication of SI1567529T1 publication Critical patent/SI1567529T1/sl
Publication of SI1567529T2 publication Critical patent/SI1567529T2/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
SI200332389T 2002-05-16 2003-05-16 Psevdopolimorfne oblike zaviralca HIV proteaze SI1567529T2 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02076929 2002-05-16
PCT/EP2003/050176 WO2003106461A2 (en) 2002-05-16 2003-05-16 Pseudopolymorphic forms of a hiv protease inhibitor
EP03753571.3A EP1567529B2 (en) 2002-05-16 2003-05-16 Pseudopolymorphic forms of a hiv protease inhibitor

Publications (2)

Publication Number Publication Date
SI1567529T1 true SI1567529T1 (sl) 2014-11-28
SI1567529T2 SI1567529T2 (sl) 2021-08-31

Family

ID=29724454

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200332389T SI1567529T2 (sl) 2002-05-16 2003-05-16 Psevdopolimorfne oblike zaviralca HIV proteaze
SI200332383T SI2314591T2 (sl) 2002-05-16 2003-05-16 Psevdopolimorfne oblike zaviralca HIV proteaze
SI200332545T SI2767539T1 (sl) 2002-05-16 2003-05-16 Psevdopolimorfne oblike inhibitorja proteaze HIV

Family Applications After (2)

Application Number Title Priority Date Filing Date
SI200332383T SI2314591T2 (sl) 2002-05-16 2003-05-16 Psevdopolimorfne oblike zaviralca HIV proteaze
SI200332545T SI2767539T1 (sl) 2002-05-16 2003-05-16 Psevdopolimorfne oblike inhibitorja proteaze HIV

Country Status (26)

Country Link
US (8) US7700645B2 (sl)
EP (4) EP2314591B2 (sl)
JP (1) JP4864320B2 (sl)
KR (2) KR101128370B1 (sl)
CN (1) CN100475819C (sl)
AP (1) AP2052A (sl)
AU (2) AU2003271740B2 (sl)
BR (1) BRPI0311176B8 (sl)
CA (1) CA2485834C (sl)
CY (3) CY1117928T1 (sl)
DK (3) DK1567529T4 (sl)
EA (1) EA007120B8 (sl)
ES (4) ES2498370T5 (sl)
HK (1) HK1081969A1 (sl)
HR (1) HRP20041061B1 (sl)
HU (1) HUE034389T2 (sl)
IL (1) IL165140A0 (sl)
LT (1) LT2767539T (sl)
MX (1) MXPA04011427A (sl)
NO (1) NO331477B1 (sl)
NZ (1) NZ536497A (sl)
PL (1) PL215151B1 (sl)
PT (3) PT1567529E (sl)
SI (3) SI1567529T2 (sl)
WO (1) WO2003106461A2 (sl)
ZA (1) ZA200410154B (sl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1088098E (pt) 1998-06-23 2011-05-25 Univ Illinois Medicamento para tratar mam?feros infectados com hiv
EA007120B8 (ru) 2002-05-16 2012-03-30 Тиботек Фармасьютикалз Лтд. Псевдополиморфные формы ингибитора вич-протеазы
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
JP4818124B2 (ja) 2003-12-23 2011-11-16 テイボテク・フアーマシユーチカルズ・リミテツド （３Ｒ，３ａＳ，６ａＲ）−ヘキサヒドロフロ〔２，３−ｂ〕フラン−３−イル（１Ｓ，１Ｒ）−３−〔〔（４−アミノフェニル）スルホニル〕（イソブチル）アミノ〕−１−ベンジル−２−ヒドロキシプロピルカルバマートの製造方法
KR101333627B1 (ko) 2005-02-25 2013-11-27 얀센 알 앤드 디 아일랜드 프로테아제 저해제 전구체 합성
WO2008055970A2 (en) * 2006-11-09 2008-05-15 Tibotec Pharmaceuticals Ltd. Methods for the preparation of hexahydrofuro[2,3-b]furan-3-ol
AR073248A1 (es) 2008-09-01 2010-10-20 Tibotec Pharm Ltd Proceso para la preparacion de (1s, 2r)-3- ((4-aminofenil) sulfonil) ( isobutil) amino)-1- bencil-2- hidroxipropilcarbamato de (3r, 3as,6ar)- hexahidrofuro-(2,3-b) furan-3- ilo (darunavir) y compuestos intermediarios utiles en dicho proceso.
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
MX2011007790A (es) * 2009-01-29 2011-11-18 Mapi Pharma Ltd Polimorfos de darunavir.
US8703980B2 (en) * 2009-09-17 2014-04-22 Siva Rama Prasad Vellanki Process for the preparation of darunavir
BR112012009956A2 (pt) 2009-10-30 2015-09-29 Lupin Ltd um novo processo para a preparação de darunavir e etanolato darunavir de tamanho de partícula.
PT2513116E (pt) * 2009-12-16 2015-10-14 Hetero Research Foundation Polimorfos de darunavir
WO2011083287A2 (en) * 2010-01-05 2011-07-14 Cipla Limited Darunavir polymorph and process for preparation thereof
JP2013518096A (ja) 2010-01-28 2013-05-20 マピ ファーマ リミテッド ダルナビル及びダルナビル中間体の調製方法
WO2011145099A1 (en) * 2010-05-20 2011-11-24 Hetero Research Foundation Crystalline hydrochloride salt of darunavir
WO2012107889A1 (en) 2011-02-10 2012-08-16 Ranbaxy Laboratories Limited Process for the preparation of amorphous darunavir
JP6122427B2 (ja) 2011-07-07 2017-04-26 ヤンセン・サイエンシズ・アイルランド・ユーシー ダルナビル複合製剤
WO2013114382A1 (en) 2011-12-05 2013-08-08 Mylan Laboratories Ltd Crystalline darunavir
EP2804869B1 (en) * 2012-01-18 2019-06-12 Aurobindo Pharma Limited Novel solvates of darunavir
CN103509031B (zh) * 2012-06-20 2016-04-27 上海迪赛诺药业有限公司 制备达芦那韦无定形物的方法
US9475821B2 (en) * 2012-07-24 2016-10-25 Laurus Labs Private Limited Process for preparation of Darunavir
US9227990B2 (en) 2012-10-29 2016-01-05 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
US9346820B2 (en) * 2013-09-11 2016-05-24 Purdue Research Foundation HIV-1 protease inhibitors having gem-di-fluoro bicyclic P2-ligands
WO2016092525A1 (en) * 2014-12-12 2016-06-16 Lupin Limited Darunavir n-propanol solvate and process for preparation thereof
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
WO2016149486A1 (en) 2015-03-19 2016-09-22 Viamet Pharmaceuticals, Inc. Antifungal compounds and processes for making
EP3496719B1 (en) 2016-08-08 2023-06-14 Hetero Labs Limited A multi-class anti-retroviral composition
BR112019002132A2 (pt) 2016-08-08 2019-05-14 Hetero Labs Limited composições anti-retrovirais
US10407438B2 (en) 2016-10-27 2019-09-10 Gilead Sciences, Inc. Crystalline forms of darunavir
CN108727401A (zh) * 2017-04-20 2018-11-02 盐城迪赛诺制药有限公司 达鲁那韦新晶型及其制备方法和应用
CN109053753A (zh) * 2018-08-05 2018-12-21 浙江大学 一种制备达卢那韦二水合物晶型的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
JPH05230044A (ja) 1992-02-21 1993-09-07 Hoechst Japan Ltd ピレタニドの新規な結晶多形
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
AU7669794A (en) 1993-08-24 1995-03-21 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
ES2150105T3 (es) 1995-02-22 2000-11-16 Aventis Pharma Ltd Piretanida amorfa, polimorfos de piretanida, proceso para su preparacion y su uso.
ZA984514B (en) 1997-05-29 1998-11-30 Merck & Co Inc Hiv protease inhibitor
GB9712253D0 (en) 1997-06-13 1997-08-13 Glaxo Group Ltd Antiviral compound
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
GB9805898D0 (en) 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
GB9807354D0 (en) 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
PT1088098E (pt) 1998-06-23 2011-05-25 Univ Illinois Medicamento para tratar mam?feros infectados com hiv
AU4828199A (en) * 1998-06-23 2000-01-10 Board Of Trustees Of The University Of Illinois, The Multi-drug resistant retroviral protease inhibitors and associated methods
EP1131303A1 (en) 1998-11-19 2001-09-12 Du Pont Pharmaceuticals Company Crystalline (-)-6- chloro-4- cyclopropylethynyl- 4-trifluoromethyl- 3,4-dihydro- 2(1h)-quinazolinone
EP1159278B1 (en) 1999-02-12 2005-11-30 Vertex Pharmaceuticals Incorporated Inhibitors of aspartyl protease
EA007120B8 (ru) 2002-05-16 2012-03-30 Тиботек Фармасьютикалз Лтд. Псевдополиморфные формы ингибитора вич-протеазы
WO2011083287A2 (en) * 2010-01-05 2011-07-14 Cipla Limited Darunavir polymorph and process for preparation thereof

Also Published As

Publication number Publication date
ES2498370T3 (es) 2014-09-24
HRP20041061A2 (en) 2006-07-31
EA200401503A1 (ru) 2005-06-30
CY1119311T1 (el) 2018-02-14
US10858369B2 (en) 2020-12-08
CA2485834C (en) 2007-07-17
ZA200410154B (en) 2005-12-28
US20170260196A1 (en) 2017-09-14
US20150336980A1 (en) 2015-11-26
NO331477B1 (no) 2012-01-16
HK1081969A1 (en) 2006-05-26
NZ536497A (en) 2006-08-31
KR20100119906A (ko) 2010-11-11
AU2003271740A1 (en) 2003-12-31
US7700645B2 (en) 2010-04-20
PL374321A1 (en) 2005-10-17
PT2314591E (pt) 2014-09-19
US20180312517A1 (en) 2018-11-01
KR101128370B1 (ko) 2012-04-23
EP2314591A1 (en) 2011-04-27
US10000504B2 (en) 2018-06-19
ES2503551T3 (es) 2014-10-07
MXPA04011427A (es) 2005-02-17
EA007120B8 (ru) 2012-03-30
IL165140A0 (en) 2005-12-18
AU2012205289A1 (en) 2012-08-09
SI1567529T2 (sl) 2021-08-31
WO2003106461A2 (en) 2003-12-24
CY1117928T1 (el) 2017-05-17
SI2314591T1 (sl) 2014-11-28
EP2767539B1 (en) 2017-07-12
US8518987B2 (en) 2013-08-27
EP2767539A1 (en) 2014-08-20
EP2314591B2 (en) 2021-02-24
NO20045409L (no) 2004-12-10
WO2003106461A3 (en) 2004-05-13
ES2638412T3 (es) 2017-10-20
PT1567529E (pt) 2014-09-09
KR20050008715A (ko) 2005-01-21
BRPI0311176B1 (pt) 2019-08-20
DK1567529T4 (da) 2021-05-10
CN1668623A (zh) 2005-09-14
AP2004003191A0 (en) 2004-12-31
US20100204316A1 (en) 2010-08-12
BR0311176A (pt) 2005-03-15
US20140171499A1 (en) 2014-06-19
JP2005533068A (ja) 2005-11-04
CA2485834A1 (en) 2003-12-24
AP2052A (en) 2009-10-05
DK2314591T3 (da) 2014-09-22
ES2728735T3 (es) 2019-10-28
EP2314591B1 (en) 2014-06-18
DK2767539T3 (en) 2017-09-11
ES2498370T5 (es) 2021-11-24
EP1567529A2 (en) 2005-08-31
SI2767539T1 (sl) 2017-10-30
LT2767539T (lt) 2017-09-25
HRP20041061B1 (hr) 2015-02-27
SI2314591T2 (sl) 2021-08-31
HUE034389T2 (en) 2018-02-28
DK2314591T4 (da) 2021-05-10
EP3045460A1 (en) 2016-07-20
PT2767539T (pt) 2017-08-28
US20210179631A1 (en) 2021-06-17
EP3045460B1 (en) 2019-04-17
CY1115665T1 (el) 2017-01-25
EP1567529B1 (en) 2014-06-18
BRPI0311176B8 (pt) 2021-05-25
US20050250845A1 (en) 2005-11-10
DK1567529T3 (da) 2014-09-15
AU2003271740B2 (en) 2010-05-13
EA007120B1 (ru) 2006-06-30
PL215151B1 (pl) 2013-10-31
JP4864320B2 (ja) 2012-02-01
ES2503551T5 (es) 2021-10-28
CN100475819C (zh) 2009-04-08
US20130303790A1 (en) 2013-11-14
EP1567529B2 (en) 2021-02-24

Similar Documents

Publication Publication Date Title
HK1081969A1 (en) Pseudopolymorphic forms of a hiv protease inhibitor hiv
PL375486A1 (en) Potent inhibitor of hcv serine protease
AU2003213776A1 (en) Carbamates as hiv protease inhibitors
EP1499336A4 (en) PROTEASE INHIBITORS
EP1483254A4 (en) INHIBITORS OF ANTI-RESISTANCE RETROVIRAL PROTEASE
AU2003263738A8 (en) Protease inhibitors
AU2001280634A1 (en) Salt forms of an hiv protease inhibitor
AU2003287325A8 (en) N-cycloalkylglycines as hiv protease inhibitors
GB0123467D0 (en) Carbocyclic HIV Protease inhibitors
AU2002305720A1 (en) Piperazine pentanamide hiv protease inhibitors
AU2003233642A8 (en) Protease inhibitors
AU2003304496A8 (en) Protease inhibitors
AU2003252417A1 (en) Protease inhibitor
IL160626A0 (en) Antiviral protease inhibitors
EP1546333A4 (en) INHIBITOR OF ASPARTYL PROTEASE IN PLACE OF NEMATODE ALLERGENE
AU153048S (en) A set of jewellery
ZA200500560B (en) Potent inhibitor of HCV serine protease
AU2002255485A8 (en) Hiv/fiv protease inhibitors
AU2003265240A8 (en) Protease inhibitors
AU2003269878A8 (en) Protease inhibitors
GB0125884D0 (en) A piece of jewellery
GB0229288D0 (en) A modification of chess
AU151187S (en) A pair of jeans
AU153057S (en) A set of jewellery
AU153862S (en) A set of jewellery